Improvements in Immune/Melanocyte Biomarkers With JAK3/TEC Family Kinase Inhibitor Ritlecitinib in Vitiligo

Vitiligo is an autoimmune depigmenting disorder with no effective and safe treatments. Its pathogenesis is not fully elucidated. This substudy of a randomized, double-blind, placebo-controlled phase 2b trial (NCT03715829) evaluated effects of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2024-01, Vol.153 (1), p.161-172.e8
Hauptverfasser:	Guttman-Yassky, Emma, Del Duca, Ester, Da Rosa, Joel Correa, Bar, Jonathan, Ezzedine, Khaled, Ye, Zhan, He, Wen, Hyde, Craig, Hassan-Zahraee, Mina, Yamaguchi, Yuji, Peeva, Elena
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biomarkers cytokines Humans inflammation JAK Janus Kinase 3 Janus kinase inhibitors Melanocytes non-segmental vitiligo Proteomics ritlecitinib Skin tyrosine kinase Vitiligo Vitiligo - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!